Nitroglycerin Therapy in Acute Cardiogenic Pulmonary Edema – Evidence‑Based Recommendations

Initial Rapid‑Onset Therapy

Administer sublingual nitroglycerin 0.4–0.6 mg immediately after diagnosis, repeating every 5–10 minutes for up to four doses while intravenous access is being obtained. This approach provides prompt symptom relief before infusion can be started. 1

Begin nitroglycerin infusion only when systolic blood pressure is ≥95–100 mmHg. Initiation below this threshold risks compromising organ perfusion. 1

In patients receiving intravenous nitrates, a regimen of 3 mg isosorbide dinitrate every 5 minutes combined with 40 mg furosemide markedly lowers the need for mechanical ventilation (13 % vs 40 %) and reduces myocardial infarction incidence (17 % vs 37 %) compared with low‑dose nitrates plus high‑dose furosemide. (Randomized controlled trial; Level A evidence). [2][3]
The same trial demonstrated that a low‑dose furosemide (≈40 mg) paired with high‑dose nitrates yields superior clinical outcomes to the opposite strategy. [2][3]

The VMAC trial, which used nitroglycerin doses of only 29–42 µg/min, likely failed to show benefit because the dosing was insufficient. Clinicians should target higher initial rates (≥10 µg/min) to achieve therapeutic effect. [2][4]

Give intravenous furosemide 20–80 mg shortly after diagnosis, but prioritize nitrate therapy over high‑dose diuretics. 1
Morphine sulfate 3–5 mg IV may be used for symptom relief; employ caution in patients with chronic lung disease or metabolic acidosis due to the risk of respiratory depression. 1

Consider sodium nitroprusside when nitroglycerin is ineffective or in the presence of severe mitral/aortic regurgitation or marked hypertension. Start at 0.1 µg/kg/min and titrate up to 5 µg/kg/min as needed. [1][5]
Nitroprusside provides more potent afterload reduction but requires arterial line monitoring and carries a risk of cyanide toxicity with prolonged infusion. 5

Arterial line placement is recommended for nitroprusside infusions, whereas it is not mandatory for nitroglycerin therapy. 5

Large registry analysis of 65,180 patients showed that intravenous nitroglycerin is associated with lower in‑hospital mortality compared with inotropes (dobutamine OR 0.46; milrinone OR 0.69). (Observational cohort; Level B evidence). [6][3]
No significant mortality difference was observed between nitroglycerin and nesiritide after propensity‑score adjustment (OR 0.95). [2][6]

La Sociedad Europea de Cardiología establece que los vasodilatadores están indicados en pacientes con insuficiencia cardíaca aguda y presión arterial sistólica (PAS) >110 mmHg, con nitroglicerina como el agente más utilizado, iniciando con 10-20 mcg/min y titulando cada 3-5 minutos según respuesta hemodinámica 7, 8
La Sociedad Europea de Cardiología recomienda el uso de nitratos IV o nitroprusiato en pacientes con PAS >110 mmHg 9
En pacientes con PAS 90-110 mmHg, los vasodilatadores pueden usarse con precaución extrema y monitorización estrecha 9, 10
Los vasodilatadores están contraindicados en pacientes con PAS <90 mmHg, ya que pueden reducir la perfusión de órganos centrales 7, 8

La dosis inicial de nitroglicerina es de 10-20 mcg/min, con titulación cada 3-5 minutos según respuesta hemodinámica 7, 8
La dosis máxima de nitroglicerina es de hasta 200 mcg/min 11
El nitroprusiato de sodio se inicia con 0.3 mcg/kg/min y se titula hasta 5 mcg/kg/min 7, 8, 11
La nesiritida se inicia con 0.015-0.03 mcg/kg/min y se titula según respuesta de presión arterial y alivio sintomático 7, 8, 10

La monitorización esencial durante la terapia vasodilatadora incluye medición frecuente de presión arterial, frecuencia cardíaca, frecuencia respiratoria y saturación de oxígeno 7, 10
Se requiere línea arterial para monitorización en pacientes con nitroprusiato 7

Los vasodilatadores IV pueden causar hipotensión, especialmente en pacientes con estenosis aórtica o disfunción renal 7, 9
La taquifilaxia es común después de 24-48 horas de tratamiento con nitratos IV, requiriendo incrementos de dosis 7

La evidencia sugiere que los vasodilatadores IV son superiores a los diuréticos en dosis altas en el tratamiento de la insuficiencia cardíaca aguda 12, 13
El uso de vasodilatadores IV se asoció con menor mortalidad en pacientes con insuficiencia cardíaca aguda 14

La transición a terapia oral debe considerarse después de estabilización debido a taquifilaxia 10
Los vasodilatadores IV pueden combinarse con diuréticos de asa (furosemida) para efecto potenciado 10, 11

The European Society of Cardiology recommends initiating GTN at 10–20 µg/min and titrating aggressively, with possible doses up to 200 µg/min to achieve hemodynamic control【15】.

Continuous monitoring of blood pressure, heart rate, respiratory rate, oxygen saturation, and urine output for at least the first 24 h is advised【16】【17】.
An initial diuretic response is considered adequate when urine output exceeds 100 mL/h over 1–2 h【16】.

If diuresis remains insufficient despite adequate left‑ventricular filling pressure, the loop diuretic dose may be doubled up to an equivalent of 500 mg furosemide, administered by infusion over 4 h for doses ≥250 mg【16】.
For persistent peripheral edema, adding a thiazide diuretic is recommended【17】.

Early application of CPAP or bilevel NIV in eligible patients rapidly reduces pulmonary edema, venous return, and work of breathing【15】【18】【16】.

Sodium nitroprusside may replace GTN in cases of ineffectiveness, severe mitral/aortic regurgitation, or marked hypertension, starting at 0.3 µg/kg/min and titrating to 5 µg/kg/min【15】.
Nitroprusside provides stronger afterload reduction but requires arterial line monitoring and carries a risk of cyanide toxicity with prolonged use【15】.
Nicardipine (5–15 mg/h IV) is an alternative for GTN resistance; start at 5 mg/h and increase by 2.5 mg every 15–30 min until target blood pressure is reached, then reduce to 3 mg/h for maintenance【15】.

Routine supplemental oxygen should not be given to non‑hypoxemic patients (SpO₂ ≥ 90 %), as it may cause vasoconstriction and lower cardiac output【17】.

Before increasing diuretic doses, verify adequate left‑ventricular filling pressure; hypotension or worsening renal function may indicate insufficient preload, prompting diuretic reduction or volume replacement【16】.

All statements are derived from peer‑reviewed evidence (European Society of Cardiology guidelines and European Heart Journal studies).